人乳腺癌中共刺激分子PD-L1、PD-L2的表达及其临床意义

PD-L1 and PD-L2 expressions in human breast cancer and their significance

目的探讨共刺激分子PD-L1、PD-L2在人乳腺癌的表达及其与临床病理特征、预后的相关性。方法采用免疫组化SP两步法检测PD-L1、PD-L2在10例正常乳腺组织、18例乳腺导管内癌和40例乳腺浸润性导管癌中的表达,并分析两种共刺激分子的表达与乳腺癌患者临床病理特征的关系。结果正常人乳腺腺上皮不表达PD-L1和PD-L2,乳腺导管内癌弱表达PDL1和PD-L2,乳腺浸润性导管癌中PD-L1和PD-L2的阳性率分别为45%(18/40)、35%(14/40),显著高于PD-L1和PD-L2在乳腺导管内癌的表达。统计学分析结果显示PD-L1和PD-L2表达与乳腺癌淋巴结转移(P<0.05)密切相关。PD-L1和PD-L2表达与ER、PR表达(P<0.05)有相关性,但PD-L1、PD-L2表达与乳腺癌其他临床病理特征无相关性。PD-L1和PD-L2表达在ER、PR、HER-2均阴性的乳腺癌患者中高表达,差异有统计学意义(P<0.05)。结论人乳腺癌癌细胞异常表达PD-L1和PD-L2,且与淋巴结转移密切相关;PD-L1和PD-L2有望成为乳腺癌免疫治疗的潜在靶点。

Purpose To investigate the expressions of co- stimulation molecules PD-L1 and PD-L2 in human breast canc- ers and their association with clinical and pathologic characteris- tics of the patients. Methods The expressions of PD-L1, PD- L2 in 10 cases of normal human breast tissue, 18 cases of ductal carcinoma in situ, and 40 cases of breast cancer were detected by immunohistochemistry SP two-step staining, and the relation- ship between their expressions and clinical and pathologic char- acteristics was evaluated. Results There was no PD-L1 or PD- L2 expression in normal breast tissue, faint expressions of PD- L1 and PD-L2 were determined in ductal carcinoma in situ.45% （18/40） PD-L1 and 35% （14/40） PD-L2 were detected in breast cancers. PD-L1 and PD-L2 expression in cancer cells were related to the lymph node metastasis, ER and PR （P 〈 0. 05）. High expression of PD-L1 and PD-L2 in breast cancer patients were correlated with negative ER, PR and HER-2 （P 〈 0. 05 ）, Conclusion PD-L1 and PD-L2 express aberrantly in breast cancer and are closely associated with the lymph node me- tastasis of breast cancer. PD-L1 and PD-L2 may be the potential immunotberapy targets of breast cancer.